

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:**Claims 1. – 13. (Canceled)**

Claim 14. (Currently amended) The multilaminate backing construction of claim 13-A multilaminate backing construction for a drug delivery device to skin comprising:

- (a) an outer layer comprising an embossable, writable and breathable material, wherein the outer layer comprises a microporous layer or a microfibrillar layer;**
- (b) a multilaminate tie layer disposed on the skin proximal surface of the outer layer, wherein the tie layer comprises a secondary drug-containing reservoir; and**
- (c) a base layer disposed on the skin proximal surface of the tie layer.**

Claim 15. (Currently amended) The multilaminate backing construction of claim 13-14 wherein the multilaminate tie layer comprises:

- (i) a first layer disposed on the skin proximal surface of the outer layer;**
- (ii) a second layer disposed on the skin proximal surface of the first layer;**
- (iii) a third layer disposed on the skin proximal surface of the second layer; and**
- (iv) a secondary drug-containing reservoir.**

Claim 16. (Original) The multilaminate backing construction of claim 15 wherein the first layer is ethylene-vinyl acetate copolymer (EVA) or low density polyethylene (LDPE) layer; the second layer is a polyethylene terephthalate (PET) layer; the third layer is ethylene-vinyl acetate copolymer (EVA); low density polyethylene (LDPE) layer, or a polyurethane layer.

Claim 17. (Cancelled)

Claim 18. (New) The multilaminate backing construction of claim 14 wherein the secondary drug-containing reservoir includes a drug.

Claim 19. (New) The multilaminate backing construction of claim 14 wherein the secondary drug-containing reservoir includes a drug and the drug is an antagonist to another drug.

Claim 20. (New) The multilaminate backing construction of claim 14 wherein the secondary drug-containing reservoir has a polymeric matrix and includes an antagonist dispersed in the polymeric matrix.

Claim 21. (New) The multilaminate backing construction of claim 14 wherein the secondary drug-containing reservoir has a thermoformable polymeric matrix and includes an antagonist dispersed in the polymeric matrix but not dissolved in the polymeric matrix.

Claim 22. (New) The multilaminate backing construction of claim 14 wherein the secondary drug-containing reservoir has a polymeric matrix and includes an antagonist in multiparticulate form dispersed in the polymeric matrix.

Claim 23. (New) The multilaminate backing construction of claim 14 wherein the secondary drug-containing reservoir has a polymeric matrix and includes particles containing an antagonist with polymeric coating dispersed in the polymeric matrix.

Claim 24. (New) The multilaminate backing construction of claim 14 wherein the outer layer controls the release of a drug that is not delivered to the skin.

Claim 25. (New) The multilaminate backing construction of claim 14 wherein the outer layer is part of a device for transdermal delivery of a drug to the skin and wherein the outer layer controls the release of an antagonist that is not delivered to the skin and the antagonist is an antagonist to the drug that is delivered to the skin.

Claim 26. (New) The multilaminate backing construction of claim 14 wherein the outer layer is part of a device for transdermal delivery of a drug to the skin, and the secondary drug-containing reservoir contains an antagonist to the drug, the antagonist being selected from a group consisting of naltrexone, methylnaltrexone, naloxone, nalbuphine, nalorphine, nalorphine dinicotinate, nalmefene, nadide, levallorphan, cyclozocine and pharmaceutically acceptable salts thereof.

Claim 27. (New) The multilaminate backing construction of claim 14 wherein the outer layer is part of a device for delivery of a drug to the skin in a direction away from the outer layer and the outer layer controls the release of an antagonist to the drug such that the antagonist is releaseable to deter drug abuse.

Claim 28. (New) The multilaminate backing construction of claim 14 wherein the multilaminate tie layer comprises:

- (i) a first layer disposed on the skin proximal surface of the outer layer;
- (ii) a second layer disposed on the skin proximal surface of the first layer;
- (iii) a third layer disposed on the skin proximal surface of the second layer; and
- (iv) a secondary drug-containing reservoir containing particles of an antagonist to a drug dispersed in a polymeric matrix in the drug-containing reservoir;

wherein the multilaminate backing construction is part of a device for delivery the drug and first layer controls release of the antagonist drug for deterrence against drug abuse.

Claim 29. (New) The multilaminate backing construction of claim 14 wherein the secondary drug-containing reservoir has a polymeric matrix and includes an antagonist that is not releasable through the base layer and wherein the outer layer is an antagonist release rate controlling layer.

Claim 30. (New) A multilaminate backing construction for a drug delivery device to skin comprising:

- (a) an outer layer comprising an embossable, writable and breathable material;
- (b) a multilaminate tie layer, the tie layer disposed on the skin proximal surface of the outer layer and including a first layer disposed on the skin proximal surface of the outer layer and at least one additional layer disposed on the skin proximal surface of the first layer, a secondary drug-containing reservoir being one of the at least one additional layer, the secondary drug-containing reservoir including a polymeric matrix with antagonist-containing particles dispersed therein, the antagonist being selected from a group consisting of naltrexone, methylnaltrexone, naloxone, nalbuphine, nalorphine, nalorphine dinicotinate, nalmefone, nadide, levallorphan, cyclozocine and pharmaceutically acceptable salts thereof; and
- (c) a base layer disposed on the skin proximal surface of the tie layer.